SWOT Analysis for Arcadia Biosciences Inc

30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Overbought by Money Flow Index (MFI)
Companies with Low Debt
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
RSI indicating price strength
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Declining Revenue every quarter for the past 2 quarters
Top Losers